Heřmanský-Pudlák syndrome (HPS), a rare autosomal recessive disorder, manifests with oculocutaneous albinism and a bleeding diathesis. However, severity of disease can be variable and is typically related to the genetic subtype of HPS; HPS type 6 (HPS-6) is an uncommon subtype generally associated with mild disease. A Caucasian adult female presented with a history of severe bleeding; ophthalmologic examination indicated occult oculocutaneous albinism. The patient was diagnosed with a platelet storage pool disorder, and platelet whole mount electron microscopy demonstrated absent delta granules. Genome-wide SNP analysis showed regions of homozygosity that included the HPS1 and HPS6 genes. Full length HPS1 transcript was amplified by PCR of genomic DNA. Targeted next-generation sequencing identified a novel homozygous missense variant in HPS6 (c.383 T > C; p.V128A); this was associated with significantly reduced
| INTRODUCTION
Heřmanský-Pudlák syndrome (HPS) is a rare autosomal recessive disorder characterized by improper formation, processing, or trafficking of lysosome-related organelles, including melanosomes and platelet delta granules (Huizing, Helip-Wooley, Westbroek, GunayAygun, & Gahl, 2008) . Ten genetic subtypes of HPS have been identified; eight are associated with genes encoding proteins in the Biogenesis of Lysosome-related Organelles Complex (BLOC)-1 (HPS-7, HPS-8, HPS-9), BLOC-2 (HPS-3, HPS-5, HPS-6), or BLOC-3 (HPS-1, HPS-4), and two are associated with genes encoding subunits of the Adaptor Protein-3 complex (HPS-2, HPS-10) (Huizing, Malicdan, Gochuico, & Gahl, 2017) .
Cellular defects in HPS lead to diverse disease manifestations, including oculocutaneous albinism and a bleeding tendency secondary to a platelet storage pool deficiency (Gahl et al., 1998; Huizing et al., 2008; Huizing et al., 2017) . Granulomatous colitis resembling Crohn's disease can affect a subpopulation of patients with HPS, and some disease manifestations are limited to specific HPS subtypes . For example, pulmonary fibrosis develops in patients with HPS-1, -2, and -4, and immunodeficiency with natural killer cell dysfunction and neutropenia manifest in patients with HPS-2 (Gil- Krzewska et al., 2017; Gochuico et al., 2012; Huizing et al., 2017) .
In this study, we report a patient who presented with severe bleeding tendency. Although oculocutaneous albinism was subclinical, ophthalmologic examination showed mild pigmentation defects and poor foveal development. A novel homozygous missense variant in HPS6 associated with absent platelet delta granules and reduced cellular levels of HPS6 mRNA and protein was identified in this patient.
| MATERIALS AND METHODS

| Editorial policies and ethical considerations
The patient provided written informed consent to protocols 95-HG-0193 (clinicaltrials.gov NCT00001456, "Clinical and Basic Investigations into Heřmanský-Pudlák Syndrome") and 04-HG-0211 (clinicaltrials.gov NCT00084305, "Procurement and Analysis of Specimens from Individuals with Pulmonary Fibrosis"). The research was conducted prospectively; the clinical studies were approved by the institutional review board of the National Human Genome Research Institute.
Clinical testing was performed at Regional Cancer Center, Johnson City, TN and the National Institutes of Health Clinical Center, Bethesda, MD. Platelet aggregation was measured by the absorbance method using the AggRam system (Helena Laboratories, Beaumont, TX). High-resolution computed tomography scans of the chest, pulmonary function tests, and platelet electron microscopy were performed as described (Ferreira et al., 2017; Rouhani et al., 2009 ).
| Genetic testing
Next Generation Sequencing (NGS) was performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory using a targeted panel (Agilent Technologies, Santa Clara, CA) encompassing 9 HPS genes (i.e., HPS1, AP3B1, HPS3, HPS4, HPS5, HPS6, DTNBP1, BLOC1S3, BLOC1S6). Large scale single-nucleotide polymorphism (SNP) analysis was performed on genomic DNA using HumanOmniExpress DNA Analysis BeadChip (Illumina, San Diego, CA) and GenomeStudio software (Illumina) as described (Bryan et al., 2017) . PCR of HPS1 using genomic DNA was performed using Platinum Pfx DNA Polymerase according to manufacturer's instructions (Invitrogen, Carlsbad, CA).
| Quantitative real-time PCR and western blot analysis for HPS6
Fibroblasts were cultured from a forearm skin biopsy as described (Stephen et al., 2017) . Dermal fibroblasts from two healthy volunteers served as normal controls; dermal fibroblasts from three adults with HPS-1 served as BLOC-3 complex controls. Experiments were performed in triplicate.
Total RNA and protein were isolated (Stephen et al., 2017) . Quantitative real-time PCR (qPCR) was performed using TaqMan primers specific for HPS6 (Thermo Fisher, Waltham, MA), and cDNA from the patient and controls was amplified using TaqMan universal PCR master mix (Thermo Fisher) as described (Stephen et al., 2017) . Results were normalized with expression of RFLP13a (Thermo Fisher) and analyzed.
Western blot analysis was performed as described (Stephen et al., 2017) . 
| Statistical analysis
Data shown are mean AE standard error of the mean. Student's t test was used to analyze significance of difference between means (GraphPad Prism, San Diego, CA).
3 | RESULTS
| Phenotypic features
The patient is a 58-year old Caucasian woman with a long history for Whole mount platelet electron microscopy testing showed virtually no delta granules (Figure 1e ).
Pulmonary function and 6-min walk test were normal. Highresolution computed tomography scan of the chest showed bibasilar juxta-pleural linear and nodular atelectasis without clear evidence of interstitial lung disease (Figure 1f ). 
| Mutation identification
| Cellular expression of HPS6
To determine whether the patient's mutation is associated with altered HPS6 expression, mRNA and protein levels were measured in her cells.
We found that HPS6 mRNA levels in this patient's dermal fibroblasts were 37% of that in normal cells (p < .001) and 36% of that in HPS-1 BLOC-3 complex controls (p < .001) (Figure 1g ). Western blot analysis showed that HPS6 protein expression in the patient's fibroblasts were 60% of that of normal controls (p < .001) and 29% of that of HPS-1 BLOC-3 complex controls (p = .008) (Figure 1h ). HPS1 and HPS4 proteins were expressed in this HPS-6 patient's cells; these results are consistent with this patient's defect in BLOC-2, and not BLOC-3.
| DISCUSSION
Heřmanský-Pudlák syndrome type 6 was diagnosed in a 58-year old woman with a history of severe bleeding and without overt oculocutaneous albinism. Patients with HPS-6 generally have mild hypopigmentation and bleeding compared to patients with other HPS subtypes, and pulmonary fibrosis has not been reported in patients with HPS-6 (Huizing et al., 2009; O'Brien et al., 2016) . However, this patient's oculocutaneous albinism was atypical, because it was asymptomatic.
Indeed, her findings of albinism were only identified by comprehensive ophthalmologic examination. In contrast to her subclinical oculocutaneous albinism, this patient had severe bleeding, including some instances of hemorrhage requiring blood product transfusions and an episode of prolonged gastrointestinal bleeding with hemodynamic instability. HPS-6 was reported in a 32-year old male with hemophilia B who also had excessive bleeding, but the patient's oculocutaneous albinism facilitated a diagnosis of HPS in that case (O'Brien et al., 2016) .
The diagnosis of HPS-6 in our patient is based upon findings of absent platelet delta granules, identification of a homozygous missense variant in HPS6 predicted to be deleterious and molecular stud- (Gochuico et al., 2012; Huizing et al., 2009; Huizing et al., 2017; O'Brien et al., 2016) . This patient's imaging studies revealed no clear evidence of interstitial lung disease, which is consistent with a diagnosis of HPS-6. In addition, establishing a diagnosis of HPS in this patient will also facilitate management of her bleeding diathesis. In general, treatment of bleeding in patients with HPS includes thrombin-soaked gel-foam for skin wounds, intravenous desmopressin for invasive procedures, and judicious transfusion of platelets to prevent or treat surgical bleeding ).
In conclusion, we report a novel homozygous c.383 T > C missense variant in HPS6 associated with low cellular levels of HPS6 mRNA and protein in an individual with subclinical oculocutaneous albinism and a history of severe bleeding. Genetic testing and platelet electron microscopy studies combined with molecular analysis in some cases are useful modalities to evaluate and diagnose HPS in patients with atypical clinical features. 
